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Abstract
Background: Advances in gamma camera technology and the emergence of a
number of new theranostic radiopharmaceutical pairings have re-awakened interest
in in vivo quantification with single-photon-emitting radionuclides. We have
implemented and validated methodology to provide quantitative imaging of 177Lu
for 2D whole-body planar studies and for 3D tomographic imaging with single-photon
emission computed tomography (SPECT)/CT.
Methods: Whole-body planar scans were performed on subjects to whom a known
amount of [177Lu]-DOTA-octreotate had been administered for therapy. The total
radioactivity estimated from the images was compared with the known amount of the
radionuclide therapy administered. In separate studies, venous blood samples were
withdrawn from subjects after administration of [177Lu]-DOTA-octreotate while a SPECT
acquisition was in progress and the concentration of the radionuclide in the venous
blood sample compared with that estimated from large blood pool structures in the
SPECT reconstruction. The total radioactivity contained within an internal SPECT
calibration standard was also assessed.
Results: In the whole-body planar scans (n = 28), the estimated total body radioactivity
was accurate to within +4.6 ± 5.9 % (range −17.1 to +11.2 %) of the correct value. In the
SPECT reconstructions (n = 12), the radioactivity concentration in the cardiac
blood pool was accurate to within −4.0 ± 7.8 % (range −16.1 to +7.5 %) of the
true value and the internal standard measurements (n = 89) were within 2.0 ± 8.5 %
(range −16.3 to +24.2 %) of the known amount of radioactivity contained.
Conclusions: In our hands, state-of-the-art hybrid SPECT/CT gamma cameras were able
to provide accurate estimates of in vivo radioactivity to better than, on average, ±10 %
for use in biodistribution and radionuclide dosimetry calculations.
Background
The gamma camera is the workhorse of nuclear medicine imaging. However, the ma-
jority of clinical studies performed using the gamma camera today are used qualitatively
and, as such, are not primarily aimed at accurately quantifying the in vivo radiopharma-
ceutical distribution. Positron emission tomography (PET) in contrast is, however,
regarded as being a quantitative imaging modality that, in addition to providing images of
the distribution of positron-emitting radionuclides in the body, allows measurements of
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radionuclide uptake in organs and tissues (e.g. standardised uptake value (SUV)) for a var-
iety of reasons such as attempting to determine the metabolic activity of a tumour, prog-
nostication or assessment of response to chemotherapy or radiotherapy. While the
gamma camera is frequently used to measure functional parameters from organs, such as
renal function, left ventricular ejection fraction, relative myocardial perfusion and thyroid
uptake, the data obtained in these settings are non-quantitative in that the analyses are
based on the count rates of the gamma rays recorded by the detector and not normally
converted to absolute values of radioactivity concentration (e.g. kBq mL−1). The reasons
for this are largely historical with PET being regarded as the only quantitative imaging
modality available using radiolabelled tracers.
In recent times, however, this situation has started to change. There are numerous rea-
sons why quantitative measurements with the gamma camera are being re-visited. These
include:
 The developments in the past 5–10 years of gamma cameras incorporating X-ray
CT scanners and improved reconstruction algorithms for emission tomography
with enhanced corrections for the attenuation and scattering of the gamma rays as
they transit the body, leading to accurate, quantitative cross-sectional single-photon
emission computed tomography (SPECT) imaging with a variety of radionuclides
 Advances in radiochemistry resulting in a new range of radionuclide therapies,
many of which co-emit gamma rays as well as beta particles, thereby facilitating the
temporal measurement by gamma camera imaging of the whole-body biodistribution
and pharmacokinetics
 Re-evaluation of existing clinical studies using single-photon radionuclides that may
benefit from a more quantitative assessment. Examples proposed include measuring
myocardial blood flow and fractional flow reserve and SUVs in 99mTc bone scans
for monitoring response to therapy [1]
 The desire to individualise radionuclide therapies for cancer subjects based on their
observed response to tracer doses to better protect critical organs such as the bone
marrow and kidneys while optimising the absorbed radiation dose delivered to the
tumours
In previous publications, we have reported our methodology for CT-based quantifica-
tion in SPECT using 99mTc and 201Tl, which we refer to as qSPECT [2, 3]. The aim of this
paper is to report on the extension of these methods to accurately estimate lutetium-177
(177Lu) radioactivity in vivo with SPECT/CT as well as applying previously published
methods to quantify 2D whole-body planar images, due the high level of recent interest
in 177Lu for radionuclide therapy applications. A previous publication from a different
group on quantitative 177Lu SPECT, which used the manufacturer’s provided software for
all calculations, showed that accuracy of approximately ±5 % could be achieved [4].
Methods
Gamma camera
The gamma cameras that have been used in this work are all hybrid SPECT/CT devices.
The models that have been used are Symbia T6 and Intevo (both from Siemens
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Healthcare, Hoffman Estates, IL, USA). Both systems have a 15.8-mm-thick scintillation
crystal for improved efficiency of detection of higher energy γ photons since much of the
routine work on these cameras involves 131I (Eγ = 364 keV),
67Ga (93, 185 and 300 keV),
111In (171 and 245 keV) and, increasingly, 177Lu (208 keV). Both systems are dual-head
detector systems and incorporate a six-slice X-ray CT scanner. All imaging used medium
energy collimators and a single pulse height analyser (PHA) gamma energy photopeak
centred on the 208-keV photon emitted by 177Lu. While the abundance of this particular
photon is only 11 % of all disintegrations, when using therapeutic amounts involving up
to 10 GBq of radionuclide, the photon flux is sufficient for adequate imaging to be per-
formed. For this reason, we have not investigated imaging other photons emitted by 177Lu
with multiple energy windows. Both systems would be regarded as state-of-the-art with
the Intevo, in particular, having enhanced reconstruction algorithms aimed at quantitative
SPECT imaging (although not yet implemented for 177Lu imaging).
177Lu
The 177Lu (t½ = 6.7 days) that has been used in this work was produced in a nuclear re-
actor by an (n, γ) reaction (ITG, Isotope Technologies Garching GmbH, Germany
and the Australian Nuclear Science and Technology Organisation (ANSTO), Australia).
Ytterbium-176 (176Yb) is irradiated to produce 177Yb which decays with a half-life of 1.9 h
to 177Lu. This method of production produces “no carrier added” (nca) 177Lu as the irradi-
ated ytterbium target is readily separated chemically from the lutetium daughter product.
An alternative method to make 177Lu using the 176Lu (n, γ) 177Lu reaction will contain
other isotopes of lutetium (176Lu, 177mLu) as contaminants in the final product.
2D quantitative planar imaging
Planar imaging was used to measure the whole-body clearance and retention of the
nca 177Lu over a number of days. We have acquired these data routinely when
treating neuroendocrine tumours (NETs) which express somatostatin receptors using
radionuclide therapy (RNT) with the chelated peptide referred to as DOTATATE
(DOTA0-(Tyr3)-octreotate where DOTA = 1,4,7,10-tetra-azacyclododecane–1,4,7,10-
tetraacetic acid) (Auspep, Melbourne, Australia). In the work reported in this paper, all
preparations of nca [177Lu]-DOTATATE followed the methods described in a recent
paper from our institution by Aslani et al. [5] and were accompanied by a 3-h amino acid
infusion in order to provide protection for the kidneys from radiation by prevent-
ing re-absorption of the [177Lu]-DOTATATE in the proximal tubules and hence enhan-
cing clearance from the kidney to the bladder. All imaging used standard acquisition
software without modification to the gamma camera, scanning bed or other hardware.
The whole-body scanning speeds varied between 10 and 20 cm min−1 depending on the
expected count rates from the subject on each day of imaging leading to total whole-body
scanning times of between 10 and 20 min.
To produce quantitative planar images, we have followed the methodology originally
described in MIRD Pamphlet #16 [6] and implemented using in-house developed soft-
ware using a high-level scientific programming language (IDL, Exelis Visual Information
Solutions, Herndon, VA, USA) on a dedicated nuclear medicine workstation (HERMES,
Nuclear Diagnostics, Stockholm, Sweden). A radionuclide transmission scan was used for
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attenuation correction. This used a 57Co sheet source normally used for quality assurance
to collect a pair of scans: the first with the transmission source placed on the face of one
detector irradiating the opposite detector in whole-body mode to measure the unattenu-
ated photon flux from the source (usually referred to as a “blank” or “reference” scan),
and the second with the identical set-up but with the subject lying on the scanning bed
prior to the injection of the radiopharmaceutical. A small flask containing non-radioactive
water was placed at the top of the field of view. A radioactive version of an identical flask
containing the same volume of water with 177Lu added was used in all scans as an internal
standard to calibrate the system and for quality assurance. Care was taken to note the po-
sitioning of the subject so that this could be reproduced accurately at each time point
when whole-body planar imaging was acquired. The subjects were then administered
their radionuclide therapy over approximately 20 min.
All planar whole-body scans after the administration of the radionuclide therapy con-
tained the flask with a known amount (~20 MBq) of 177Lu for the internal calibration.
The count rate measured over time from the flask was also used to assess the observed
decay of the source and whether this agreed with the known value for the half-life of
177Lu. In this way, any effects such as changes in the dead time of the detector system,
variations in the scanning bed speed or background contamination would likely be ob-
served. Both detector heads were used to acquire the subject data so that a geometric
mean (GM) whole-body planar image was produced during the analysis, as described
in the MIRD methodology.
The software that was used to produce the quantitative whole-body planar images
was developed in-house in IDL. The radioactivity estimated in the jth pixel in the GM








where Aj is the radioactivity (in kBq) in the jth pixel, IA and IB are the anterior and pos-
terior count rates for the jth pixel derived from the images, the exponential term (−μet)
is the attenuation measured from the ratio of the reference-to-transmission scan, fj is a
term which accounts for the source self-attenuation [6] and C is a calibration factor
(cps kBq−1) derived from the internal standard. An adjustment for the difference be-
tween the energy of the gamma photons from 57Co (122 keV) to 177Lu (208 keV) is re-
quired (see Table 1). This conjugate view GM technique allows determination of
activity within the volume of interest without requiring knowledge of the depth of the
source region and without dependence upon assumptions inherent in single-view im-
aging. At the conclusion of processing, the images are stored with units of kilobec-
querel in such a way that the total number of events in the image is equal to the
radioactivity in standard units (kBq). Figure 1 shows an example of the data that are
used in this process. Note that unlike many investigations using radionuclides, decay
correction is not applied to these time series data as the radioactivity present within
the body provides the therapeutic effect and, as such, the total radioactivity present at
the time of imaging is the desired parameter. It would be appropriate to apply decay
correction to a study where, for example, the biodistribution and whole-body retention
of a radiolabelled therapeutic pharmaceutical were the parameter of interest. This is
not, however, the case for radionuclide therapies.
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Table 1 Parameters used in the processing of the quantitative planar and SPECT data
Imaging
mode
Parameter Value Units Comment
Planar Attenuation coefficient in water: 57Co 0.125 cm−1 Used in scaling transmission scan;
broad-beam value
Planar Attenuation coefficient in water: 177Lu 0.090 cm−1 Used in scaling transmission scan;
broad-beam value
SPECT Transmission-dependent scatter correction
parameter: A
2.15 – Constant used in scatter
correction of 177Lu data
SPECT Transmission-dependent scatter correction
parameter: B
1.15 – Constant used in scatter
correction of 177Lu data
SPECT Transmission-dependent scatter correction
parameter: β
0.29 – Constant used in scatter
correction of 177Lu data
SPECT FWMH of Gaussian in transmission-dependent
scatter correction kernel
0.344 cm−1 Constant used in scatter
correction of 177Lu data
SPECT Attenuation coefficient in water: 177Lu 0.110 cm−1 Used for attenuation correction
of SPECT; narrow-beam value
Fig. 1 Planar whole-body scans from one individual for the blank (left) and transmission scans (middle) both
using a 57Co sheet source and the initial geometric mean whole-body emission scan commencing approximately
30 min after the [177Lu]-DOTATATE infusion (right) are shown. Due to the very high contrast in the emission scan,
it has been histogram normalised to more effectively display the full range of the data. Numerous
metastatic lesions (yellow spots) are seen in the emission image. The calibration source is clearly visible above
the head of the subject
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3D quantitative SPECT imaging
The methodology that we have developed and previously reported for quantitative
SPECT [2, 7–9] has been adapted for imaging the 177Lu distribution in vivo, with ap-
propriate modifications for the radionuclide. This uses the CT scan with conversion
from Hounsfield units to attenuation coefficients for attenuation correction and for
transmission-dependent scatter correction [10]. An iterative reconstruction algorithm
(ordered subset estimation maximisation (OSEM)) [11] was used for the SPECT image
reconstruction. This methodology, while originally developed for diagnostic studies, is
well-suited to imaging therapeutic levels of 177Lu in vivo as, in spite of the relatively
low gamma photon abundance for the 208-keV photon from 177Lu, the amount admin-
istered (~GBq) readily lend these studies to producing images of high quality with a
satisfactory event rate for detection. The event rates detected in the initial few days of
imaging resemble those from a diagnostic 99mTc bone scan. The imaging characteristics
of 177Lu were assessed in a series of phantom experiments, as we have done for other
radionuclides, to derive parameters such as system sensitivity and the a priori constants
(A, B, β, μ) used in the scatter and attenuation correction procedures. These are con-
tained in Table 1. Apart from these different optimising parameters, the methodology
that we have previously published was unchanged. The images thus produced display
the data as a concentration unit (kBq mL−1) per voxel.
To validate the methodology in the reconstructed clinical images, we have used two
approaches: (a) all SPECT acquisitions included a plastic flask containing water
(~125 mL) with a calibrated amount of 177Lu added (~40 MBq) that acted as an in-
ternal standard to check the accuracy of the reconstruction and (b) an in vivo approach
similar to that which we have previously employed with blood pool imaging, using the
concentration of the radionuclide in a venous blood sample taken at approximately the
mid-point of the SPECT acquisition to compare to the reconstructed concentration of
radioactivity in the images [7].
Imaging protocol
The imaging protocol we have used originally acquired planar whole-body images com-
mencing immediately at the end of the radionuclide therapy infusion (~30 min after the in-
fusion commenced) and again at approximately 4, 24 and 96 h post-infusion. These were
supplemented with SPECT/CT scans of the upper abdomen at the 4, 24 and 96 h time
points. In the SPECT scans, the time per projection was initially 10 s for 60 views/detector
leading to a total imaging time of approximately 10–12 min. This was increased in the lat-
ter imaging time points initially to 15 s per projection and then 20 s per projection, thus re-
quiring a little over 15–20 min per scan, respectively. After acquiring a large number of
planar whole-body scans (~30) at the early imaging time point, we discontinued this and
replaced it with a SPECT/CT scan immediately after the infusion ceased. During this scan,
a blood sample was taken for determining the radioactivity concentration in whole blood
with an automated laboratory bench-top gamma counter. The technical parameters for the
protocol are contained in Table 2. All subjects were treated as outpatients not requiring
hospitalisation and returned to their homes or current lodgings at the end of each day.
The imaging protocol described was repeated for all cycles of radionuclide therapy
for both cohorts. In this way, we were able to assess the accuracy and reproducibility of
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the whole-body clearance, retention and uptake of the radionuclide administered for
therapy. A summary of the imaging acquisition protocols is contained in Table 2.
Subject details
Cohort 1
In the initial series of scans (cohort 1), we acquired planar whole-body (anterior/posterior)
images of the subjects immediately after the end of the [177Lu]-DOTATATE infusion prior
to voiding. Thus, by accurately knowing the amount of 177Lu that was administered from
the dose calibrator measurements before and after the injection, we were able to compare
the known total amount of radioactivity contained in the subject’s body with that esti-
mated from the planar gamma camera images.
Table 2 Acquisition parameters for all time points. A medium energy collimator and a single PHA
energy window of 208 keV ± 10 % were used for all acquisitions
Approx. time from
injection (h)
Cohort Acquisition Parameters Comments
Morning of RNT Both Blank planar WB scan 57Co sheet source;
10 cm min−1; range
0–199 cm; matrix
1024 × 256
−1 Both Transmission planar
WB scan
57Co sheet source;
10 cm min−1; range
0–199 cm; matrix
1024 × 256
Prior to administration of
[177Lu]-DOTATATE
0.5 1 Whole-body planar
emission scan
177Lu; 20 cm min−1;
matrix 1024 × 256
Prior to voiding—100 % of
administered radioactivity
remaining in subject





step and shoot mode;
acquisition matrix
128 × 128
Venous blood sample taken
at mid-point of scan
~4 Both Whole-body planar
emission
177Lu; 20 cm min−1;
matrix 1024 × 256









increased due to lower
retained radioactivity
~24 Both Whole-body planar
emission
177Lu; 10 cm min−1;
matrix 1024 × 256





step and shoot mode;
acquisition matrix
128 × 128
Time per projection increased
to reflect decreased overall
retained radioactivity
~96 or 120 Both Whole-body planar
emission
177Lu; 10 cm min−1;
matrix 1024 × 256





step and shoot mode;
acquisition matrix
128 × 128
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Cohort 2
A second group of subjects had SPECT/CT scans acquired immediately at the conclu-
sion of the [177Lu]-DOTATATE infusion, but in this case, they were allowed to empty
their bladder prior to commencing the data acquisition. The study commenced ap-
proximately 40 min after the start of the infusion, chosen as this is a time when the
concentration of [177Lu]-DOTATATE in the blood is still reasonably high. The same
procedure was initially attempted at the 4-h time point during SPECT/CT acquisition;
however, the clearance from the blood was so rapid in most subjects that it was difficult
to reliably measure the blood concentration of 177Lu in the SPECT images at this time.
Therefore, in spite of the fact that the rate of clearance is rapid and hence the change
in concentration in the blood during the acquisition is likely to be a confounding factor,
it was decided to measure the blood pool early to give the best possible image quality
for the measurements.
Venous blood was withdrawn from the cannula that was being used for the amino
acid infusion, and was taken at approximately the mid-point of the SPECT acquisition;
the acquisition was suspended temporarily if required for the sample to be taken. Sap-
onin (Sigma-Aldrich, Sydney, Australia) was added to the blood sample to lyse the red
cells to produce a homogeneous mixture. Half millilitre aliquots of the lysed whole
blood were transferred by pipette to counting tubes for the automatic gamma counter
(Wizard2 Automatic Gamma Counter 2480, PerkinElmer, Waltham, MA, USA) and
counted with a 177Lu standard prepared on each day of therapy. The samples were gen-
erally counted within 4–24 h after the blood sample was taken.
Data analysis
In cohort 1, the image-estimated total radioactivity at the initial imaging time point
was compared with the net amount administered to the subject based on measurements
in a dose calibrator of the syringe containing the [177Lu]-DOTATATE before and after the
administration of the radionuclide therapy. No account for retained radioactivity in the in-
fusion lines and cannula was included. Due to the way that the software has been written,
the total radioactivity in the geometric mean whole-body planar images is equivalent to
the total number of events (“counts”) in the image. The difference between the known
amount of therapy administered and the image estimate was calculated for each time
point as:
Difference %ð Þ ¼ image estimate MBqð Þ−calibrated dose MBqð Þð Þ
calibrateddose MBqð Þ  100
Thus, a positive value for the difference indicates an overestimate in the whole-body
image while a negative value indicates an underestimate of the amount of radioactivity
in the body.
In cohort 2, the blood sample measured in the gamma counter was compared to a
standard made up on the day to convert counts per minute (cpm) from the counter to
kilobecquerel per millilitre and decay corrected from the time of counting back to the
mid-point of the SPECT acquisition. The blood pool concentration was measured in
the reconstructed images with the voxel values displayed in units of kilobecquerel per
millilitre. The data over five contiguous planes were averaged to improve the signal to
noise ratio. A circular ROI was placed over the middle of the thoracic vasculature
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(cardiac blood pool), and all pixels above 80 % of the maximum value within the region
were used as a mask to identify the vascular structures. The mean value and standard
deviation within these pixels were recorded and an overall mean and standard deviation
of the means calculated.
In the SPECT studies containing the internal standard (cohorts 1 and 2), the total
radioactivity contained within the flask was estimated from the images by placing a
generous, or “loose”, region of interest (ROI) around the flask on a representative trans-
verse slice with the reconstructed voxel values summed over all slices containing the
flask. The known amount of 177Lu contained in the flask was calculated with a dose
calibrator by measuring the difference between the amount contained in the dispensing
syringe before and after it was added to the flask. A new calibration standard was made
up for each initial day of imaging, but only one standard was used for all subjects
treated on the same day and in all subsequent imaging (i.e. up to day 4 or 5). The re-
sults are expressed as the total radioactivity estimated in the flask from the images
compared to the calibrated amount dispensed.
Results
2D quantitative planar imaging
Twenty-eight whole-body planar scans were acquired at the initial 30-min time point
in nine individuals undergoing RNT, immediately after the completion of the [177Lu]-
DOTATATE infusion. All subjects had previously been diagnosed with a histologically
confirmed metastatic neuroendocrine tumour (NET), had demonstrated good uptake
in the NET lesions on [68Ga]-DOTATATE PET/CT imaging and met all other inclusion
criteria for RNT with [177Lu]-DOTATATE. An example of processed quantitative
whole-body planar data is shown in Fig. 2 for all time points of a single cycle for one
subject. Indicated in the text under each image is the estimated radioactivity in each
scan and the fraction expressed as a percentage of the radioactivity in the first image,
taken to be 100 %.
Table 3 shows the relevant subject characteristics and results for cohort 1, the dose
calibrator measures of the administered amounts and the image-based estimated total
radioactivity for the 26 initial whole-body planar scans. The estimated total body radio-
activity of 177Lu had an average error of +4.6 ± 5.9 % with a range −17.1 to +11.2 %.
Within an individual subject, the average difference between measured and estimated
total radioactivity was in the range −4.0 to +7.9 %.
3D quantitative SPECT imaging
In cohort 2, 12 SPECT studies with blood samples taken during the early scan, acquired
immediately after the end of the administration of the RNT, were acquired from six
subjects. Table 4 contains all results for these measurements. There was a general ten-
dency to underestimate the radioactivity concentration in the SPECT images of the
blood pool using the previously defined experimental parameters for SPECT imaging of
177Lu on the particular gamma camera, collimator energy, PHA window and radio-
nuclide used. The mean error was −4.0 ± 7.8 % with a range −16.1 to +7.5 %.
We measured the total radioactivity in the calibration flask in 89 separate SPECT ac-
quisitions from nine subjects each having up to four cycles of RNT—for each cycle, we
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have 3–4 SPECT acquisitions corresponding to the time points 0.5, 4, 24 and 96 or
120 h after administration (Table 4). An example of a maximum intensity projection
(MIP) from a SPECT study at the 0.5-h time point showing the location of the calibra-
tion flask relative to the subject can be seen in Fig. 3. The average estimated difference
between the radioactivity in the standard in the image and the amount dispensed as
measured by the dose calibrator was +2.0 ± 8.5 % with a range of −16.2 to +24.2 %.
Discussion
The recent introduction of a number of new theranostic radiopharmaceutical pairs has
been an impetus for renewed interest in quantitative imaging with the gamma camera.
These developments in synthetic radiochemistry have been accompanied by increasing
utility of hybrid SPECT/CT gamma cameras and improvements in algorithms for quan-
titative image reconstruction. In this paper, we have re-introduced procedures docu-
mented more than 15 years ago [6] to produce quantitative 2D whole-body planar
images for the therapeutic radionuclide 177Lu. In addition, we have applied techniques
that we have previously developed for quantitative 3D SPECT imaging with 99mTc and
201Tl [2] to 177Lu. While whole-body 3D quantitative SPECT imaging at multiple time
points, such as available with PET, still remains challenging for SPECT, we are,
nevertheless, able to characterise much of the biodistribution and time-course of
Fig. 2 Whole-body quantitative planar scans for one subject (subject C in Table 3) for a single cycle from 0
to 96 h (approx.). The estimated retained radioactivity is estimated to be 8878, 3456, 1865 and 614 MBq for
each of the time points, corresponding to 100, 39, 19 and 7 % retained, respectively. The calibration standard
seen in Fig. 1 is removed by the software before the determination of the total radioactivity retained
in the subject
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Table 3 Subject characteristics and results of planar whole-body radioactivity measurements for cohort 1. The height, weight and BMI (body mass index) are included to allow
correlation between general measures of body habitus and the results from quantitative imaging
Identifier Primary Dx Height (cm) Weight (kg) BMI (kg/m2) Cycle Administered (MBq) Measured (MBq) Difference (%) Subject average
difference (%)
A Small bowel NET 170 66 23 1 6232 6378 2.3 5.8
2 8505 9327 9.7
3 7515 8215 9.3
4 7803 7956 2.0
B Pancreatic NET 177 88 28 1 6780 6494 −4.2 2.9
2 8434 9110 8.0
3 8505 9060 6.5
4 7599 7708 1.4
C Breast NET 169 77 27 1 7985 7767 −2.7 4.2
2 9096 9516 4.6
3 7996 8878 11.0
4 7821 8133 4.0
D Rectal NET 178 66 21 1 8711 9410 8.0 9.6
2 7614 8465 11.2
E Small bowel NET 150 79 35 1 7971 8542 7.2 4.4
2 7669 7689 0.3
3 7930 8392 5.8
4 8100 8012 −1.1
F Meningioma 180 88 27 1 7928 8730 10.1 7.9
2 7560 8042 6.4












Table 3 Subject characteristics and results of planar whole-body radioactivity measurements for cohort 1. The height, weight and BMI (body mass index) are included to allow
correlation between general measures of body habitus and the results from quantitative imaging (Continued)
G Meningioma 168 68 24 1 7827 8529 9.0 6.0
2 7391 7923 7.2
3 7897 8036 1.8
H Adrenal phaeochromocytoma 175 69 23 1 7618 8127 6.7 6.3
2 7484 7925 5.9
I Pancreatic NET 183 93 28 1 7115 5898 −17.1 −4.0
3 8160 8902 9.1













radiopharmaceuticals labelled with 177Lu using current generation state-of-the-art
multimodal gamma cameras.
Quantification of 2D planar whole-body imaging allows us to study the retention of
the radiopharmaceutical in an individual subject. This is the first step towards estimat-
ing individual organ and tissue uptake. Absolute quantification is not essential for
studying total body retention as this can be achieved by simply measuring the subject
immediately after administering the radiopharmaceutical and calculating subsequent re-
tention values as a fraction of the initial total count. The method implemented in this
paper, being an absolute measure, relaxes this constraint, thus allowing whole-body es-
timates to be made at any time point without the initial “100 % of dose” image against
Table 4 Results comparing the whole blood and image-derived radioactivity concentration mea-
surements for cohort 2
Identifier Gamma counter blood activity (kBq mL−1) SPECT average blood activity (kBq mL−1) Difference (%)
1 317 298 −6.0
2 411 375 −8.8
3 404 349 −13.6
4 271 287 5.9
5 170 158 −7.1
6 150 142 −5.3
7 323 308 −4.8
8 302 315 4.3
9 301 274 −9.0
10 316 265 −16.1
11 360 387 7.5
12 235 246 4.7
Mean −4.0
SD 7.8
Fig. 3 A MIP image from the initial SPECT study (0.5 h after administration of the therapy commenced) for
one subject is shown, indicating the location of the calibration flask (yellow arrow) relative to the subject.
The kidneys (red) are seen to be the organs with the highest uptake at this imaging time point. Subject’s
right side (R) and left side (L) are indicated
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which all other relative measures are based. The estimation of the radioactivity as the
percentage of injected dose (%ID) in individual organs and tissues over time, however,
requires a quantitative approach. Organ dosimetry based on 2D planar imaging has
limitations due to the superimposition of different organs and tissues in the image and
is therefore limited. However, such measurements are still generally acceptable when
estimates of organ dosimetry are required. In time, it is likely that all radionuclide
organ dosimetry estimates will be obtained with tomographic imaging, whether from
PET or SPECT [12, 13], but currently, 2D planar whole-body imaging remains the
standard. A potential problem that can arise when producing pixel-by-pixel geometric
mean images from conjugate views, as opposed to calculating the geometric mean of
two count rates from larger ROIs, is that in areas of low count rate a pixel containing a
zero value may be encountered and thus will produce a geometric mean of 0. This
would not happen with an arithmetic mean. The effect of this would be to underesti-
mate the mean count rate and hence the radioactivity contained. This happens fre-
quently if a background region outside the body is sampled. This underestimation is
unlikely to be a problem with the [177Lu]-DOTATATE images we are using due to the
large amounts of radioactivity administered in this therapeutic regime and subsequently
the high total number of events that are recorded. In the scenario where 177Lu might
be used as a tracer study prior to therapy, however, this could be a source of error.
We have shown in this paper that previously published methodology can be applied
to planar whole-body imaging for 177Lu with sufficient accuracy for dosimetry calcula-
tions. Using the techniques described in this paper, we have recently reported on the
biodistribution and radiation dosimetry from nca [177Lu]-DOTATATE [14], and this
will be the subject of a future manuscript.
Quantitative SPECT imaging is a subject that has recently been receiving increasing
attention [4, 15–18]. It is likely to increase even further as algorithms are developed
with a primary focus on producing quantitative image data. Additionally, radionuclides
that are used for therapeutic applications are generally more likely to produce gamma
emissions than positrons and therefore will always be more suitable to imaging with
the gamma camera/SPECT, or other single-photon imaging device, than with PET. One
notable exception to this is the relatively recent introduction of imaging therapeutic
90Y distributions with the PET camera [19, 20]. Whole-body SPECT/CT imaging at
multiple time points, while possible, still places excessive demands on the individuals
being imaged due to the lengthy acquisition times and hence is not commonly used
today. We have combined whole-body planar imaging with regional SPECT/CT im-
aging over organs and tissues of interest at multiple time points to better characterise
the delivery and retention of radionuclide therapy with [177Lu]-DOTATATE.
In this paper, we have demonstrated that quantitative imaging with the gamma cam-
era using whole-body planar and SPECT/CT methods can produce images accurate to
better than ±10 % on average of the true value. The planar image tended to overesti-
mate the true radioactivity amount (by ~5 % on average) while the SPECT studies
tended to underestimate the radioactivity concentration by a similar amount (−4 % on
average). The check of the internal standard in SPECT was, in general, extremely ac-
curate. In two of the subjects, the radioactivity concentrations were underestimated
by >10 % (subject identifier #3: −13.6 % and subject identifier #10: −16.1 %). In fact,
the results for subjects with identifiers 1, 2 and 3 are the same individual measured
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during different cycles, and the same is also true for subject identifiers 7, 8, 9 and 10
(in a different individual). As can be seen in Table 3, the larger error seen for identi-
fier 3 is worse than for identifiers 1 and 2, and likewise the error in estimation for
identifiers 7, 8, and 9 are less than that seen for identifier 10. A check of the accuracy
of the internal standard in the study with identifier 3 reveals an error of −2.2 %, and
for identifier 10, the error in the internal standard was +1.7 %. Therefore, the larger
errors seen when measuring the blood pool radioactivity concentration are unlikely to
be systematic errors due to a common problem (e.g. global dead time) and are more
likely related to issues in obtaining the sample. As mentioned previously, the rate of
change of the radioactivity concentration is very great in the first few hours after ad-
ministration of [177Lu]-DOTATATE in subjects with good renal function. However, in
general, the values obtained are likely to be acceptable for most quantitative work in
nuclear medicine imaging, particularly radiation dosimetry estimation, given the other
factors that contribute to the derivation of such estimates.
These results with 177Lu are consistent with previous publications that have tested
the accuracy of SPECT reconstructions using diagnostic imaging radionuclides such as
99mTc, 123I and 201Tl [2, 7–9, 15, 16, 21–24].
We have used the quantitative SPECT data to estimate the radiation-absorbed dose
to the kidneys, which is seen as the organ most at risk, with each cycle of [177Lu]-
DOTATATE therapy. This paper reports on the accuracy of in vivo measurements in
human subjects, rather than experimental phantom studies, and as such demonstrates
the ability of the imaging techniques to provide meaningful quantitative data in clinic-
ally relevant situations. We are also able to estimate the radiation absorbed dose to any
neoplastic lesions in the same field of view; however, other lesions throughout the body
have not generally been imaged due to the need for additional SPECT acquisitions to
cover these regions. We envisage that improvements in reconstruction algorithms may
lead to a reduction in acquisition times which then may be used to study multiple re-
gions of the body in the same total scan time as is currently required.
We have used internal standards of the same radionuclide for both the planar whole-
body and SPECT measurements extensively in these studies. We consider that this pro-
vides useful additional information plus internal quality assurance for any absolute
quantification regime. In the planar whole-body studies, the standard is used to (a)
check the sensitivity (cps kBq−1) in whole-body scanning mode, which varies with
changes in the scanning bed speed, as well as (b) assessing that the total number of
events measured in the flask decreases with time due to radioactive decay which can be
used to verify that the gamma camera is behaving in a linear fashion and is not being
unduly compromised by, for example, high dead time. In the SPECT studies, the cali-
bration standard is used (i) to check the accuracy of the recovered total radioactivity in
the standard in the reconstructed images and (ii) to check that the reconstructed total
radioactivity decreases over time again due to radioactive decay and produces a good
estimate of the physical half-life of the radionuclide in question.
Conclusions
The quantitative data that we have produced with these techniques can be used to esti-
mate a variety of parameters of interest in radionuclide therapy including total body
retained radioactivity (for radiation safety purposes), planar MIRD-based internal
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radionuclide dosimetry, 3D estimates of radiation dosimetry per cycle to target tissues
(neoplasia) and to organs at risk (e.g. kidneys), and to monitor changes over time, for
example, changes in uptake in response to the therapy. As we now regard SPECT as a
quantitative tool, further investigations that were not previously possible can now be
undertaken such as examining the potential impact of concomitant “modulating” or
“blocking” pharmaceuticals on therapeutic radiopharmaceutical uptake.
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